Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237824 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| SCHEMBL16237326 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| SCHEMBL6413946 | 0.90 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| SCHEMBL2393939 | 0.81 | — | — | |
| SCHEMBL28244684 | 0.78 | — | — | |
| SCHEMBL37603 | 0.70 | — | — | |
| SCHEMBL419917 | 0.70 | CCR2 (0.31) | — | |
| SCHEMBL16246596 | 0.68 | CCR2 (0.36) | CYP2D6 | |
| SCHEMBL12632397 | 0.68 | — | — | |
| SCHEMBL9425244 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177190-B1 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI CHEM PHARM (IT) | 2005-11-02 | — | — | EP | claimed |
| JP-2002544158-A | — | — | 2002-12-24 | — | — | JP | claimed |
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. | 2002-10-31 | — | — | US | claimed |
| EP-1177190-A2 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-02-06 | — | — | EP | claimed |
| US-6303606-B1 | FOR THERAPY OF SEXUAL DISORDERS | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-16 | — | — | US | claimed |
| WO-2000067735-A2 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2000-11-16 | — | — | WO | claimed |
| WO-2025098503-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-119461413-A | Method for synthesizing ammonia by activating nitrogen under mild condition by using liquid organic material | 大连理工大学 | 2025-02-18 | — | — | CN | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| CN-109963849-B | Nitrogen-containing heterocyclic compounds as FXR modulators | 和博医药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-03-18 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. | 2002-10-31 | — | — | US | disclosed |
| CN-1354749-A | Use of selective antagonists of 1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI CHEM PHARM (CH) | 2002-06-19 | — | — | CN | disclosed |
| EP-1177190-A2 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-02-06 | — | — | EP | disclosed |
| US-6303606-B1 | FOR THERAPY OF SEXUAL DISORDERS | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-16 | — | — | US | disclosed |
| WO-2000067735-A2 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2000-11-16 | — | — | WO | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | ADRA1B, ADRA2B, ADRB2 | CHRNB2 28/4885CHRNA7 49/4885CHRNA4 76/4885 |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NPY2R, NPY5R, RXFP1 | CHRNB2 1064/4885CHRNA7 806/4885CHRNA4 1534/4885 |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | NR1H4, FXR1, FXR2 | CHRNB2 4611/4885CHRNA7 4711/4885CHRNA4 4654/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | CHRNB2 1233/4885CHRNA7 821/4885CHRNA4 1528/4885 |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | NR1H4, FXR1, FXR2 | CHRNB2 4611/4885CHRNA7 4711/4885CHRNA4 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.